Evidence map›Paper›PMID 39496899›Full record

ArticleAnnals of surgical oncology2025

Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Using Open and Closed Abdomen Techniques for Colorectal Peritoneal Metastases and Peritoneal Pseudomyxoma Recurrences: Results from Six French Expert Centers.

Fatah Tidadini, Catherine Arvieux, Olivier Glehen, Isabelle Sourrouille, Frédéric Marchal, Julio Abba, Brice Malgras, Jean-Louis Quesada, Marc Pocard, Anne-Cécile Ezanno

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fatah TidadiniDepartment of Digestive and Emergency Surgery, Grenoble-Alpes University Hospital, Grenoble, France. FTidadini@chu-grenoble.fr.
Catherine ArvieuxDepartment of Digestive and Emergency Surgery, Grenoble-Alpes University Hospital, Grenoble, France.
Olivier GlehenLyon Center for lnnovation in Cancer, Lyon 1 University, Lyon, France.
Isabelle SourrouilleDepartment of Surgical Oncology, Gustave Roussy Cancer Center, Villejuif, France.
Frédéric MarchalDepartment of Digestive Surgery, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France.
Julio AbbaDepartment of Digestive and Emergency Surgery, Grenoble-Alpes University Hospital, Grenoble, France.
Brice MalgrasDepartment of Digestive Surgery, Begin Military Teaching Hospital, Saint Mandé, France.
Jean-Louis QuesadaDepartment of Digestive and Emergency Surgery, Grenoble-Alpes University Hospital, Grenoble, France.
Marc PocardDepartment of Digestive Surgery, La Pitié Salpêtrière Hospital, Paris, France.
Anne-Cécile EzannoDepartment of Digestive Surgery, Begin Military Teaching Hospital, Saint Mandé, France. ezanno.annececile@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStandard treatment for resectable peritoneal metastases (PM) combines cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC); however, the rate of recurrence remains high and repeat CRS/HIPEC may be considered in well-selected patients. We describe our postoperative and oncological outcomes.

methodsBetween 1994 and 2024, data from 132 repeat CRS/HIPEC procedures were analyzed in this retrospective multicenter study. Morbimortality, overall survival (OS) and recurrence-free survival (RFS) were evaluated for colorectal peritoneal metastases (CRPM) and peritoneal pseudomyxoma (PMP).

resultsOverall, 63 patients, including 55 patients with CRPM (87.3%) and 8 patients with PMP (12.7%), underwent CRS/HIPEC. Of these patients, 58 (92%) underwent CRS/HIPEC twice, 4 (6.3%) underwent CRS/HIPEC three times, and 1 (1.6%) underwent CRS/HIPEC four times. Peritoneal Carcinomatosis Index (PCI) score, operating room occupancy, complication and readmission rates at day 90, and length of intensive care unit and hospital stay were similar between the initial and first repeat CRS/HIPEC procedures. No 90-day postoperative mortality occurred. For CRPM, the median OS was 82.3, 53.9, and 74.5 months from the initial, first, and second repeat CRS/HIPEC procedures, respectively, with a median RFS of 22.0, 36.9, and 13.2 months, respectively. For PMP, after a median follow-up of 70.8 and 39.3 months from the initial and first repeat CRS/HIPEC procedures, respectively, all patients were alive, with a median RFS of 22.4 and 39.4 months, respectively. Multivariate analysis shown that no factor was significantly related to severe complications (Dindo-Clavien 3-4) or OS.

conclusionsIn selected patients with CRPM and PMP, CRS/HIPEC shows comparable results between the initial and repeat procedures in terms of postoperative outcomes, and appears to improve survival, especially for PMP. Repeat CRS/HIPEC is an option to be considered in patients presenting with CRPM or PMP.

Indexed as

Colorectal NeoplasmsCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyNeoplasm Recurrence, LocalOpen Abdomen TechniquesPeritoneal NeoplasmsPseudomyxoma PeritoneiAdultAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, Cancer, Regional PerfusionCombined Modality TherapyFemaleFollow-Up StudiesFranceHumansColorectal peritoneal metastasesCytoreduction surgery (CRS)Hyperthermic intraperitoneal chemotherapy (HIPEC)Oncological outcomesPeritoneal pseudomyxomaRepeat CRS/HIPEC

Identifiers

PMID39496899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.